Mobile website
Influence of phosphorothioate-modified antisense VEGF oligodeoxynucleotides formulated in cationic liposome on blood flow of lung cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
investigate whether phosphorothioate-modified antisense vascular endothelial growth factor oligodeoxynucleotides ( VEGF-ASODN) formulated in cationic liposome can inhibit the blood flow of lung cancer. Methods: Lewis lung tumor models were established by subcutaneous injection of Lewis lung carcinoma cells into the right flank of 40 C57BL/6 mice. Twenty-four hours later, mice were randomly assigned into 4 groups; pure liposome, liposome containing ASODN, SODN and MODN. Mice in each group were treated twice a week for 4 weeks. Tumor growth were determined. Peak systolic flow velocity (PS) and resistance index (RI) were measured with a sonographic scanner. Expression of VEGF mRNA were detected by hybridization in situ and RT-PCR. Results: ASODN significantly suppressed the growth of subcutaneous tumors. PS and RI in VEGF-ASODN group were significantly different from those in other 3 groups ( P < 0. 01 ). ASODN markedly downregulated the expression of VEGF at level of mRNA. Conclusion:It is demonstrated that the phosphorothioate-modified ASODN can significantly suppress the growth of tumor by damaging the blood flow of lung cancer.
Keywords:
Project Supported:
Clc Number:
